Momenta’s neuromuscular drug looks competitive in Phase 2
Momenta Pharmaceuticals’ treatment for the rare neuromuscular disease myasthenia gravis posted impressive results in a mid-stage study, improving the company’s odds of competing with a more advanced rival.
As STAT’s Adam Feuerstein reports, Momenta’s drug improved symptoms for 52% of patients with generalized myasthenia gravis, beating the 15% seen with placebo. Momenta tested four different doses of its treatment in the Phase 2 study, and it’s likely to use a monthly dose in its next study, which would support FDA approval.
The news, which sent Momenta’s share price up about 15% yesterday, suggests the company has a shot against Argenx, a Belgian drug maker whose myasthenia gravis treatment could be up for approval later this year.
Read more.
As STAT’s Adam Feuerstein reports, Momenta’s drug improved symptoms for 52% of patients with generalized myasthenia gravis, beating the 15% seen with placebo. Momenta tested four different doses of its treatment in the Phase 2 study, and it’s likely to use a monthly dose in its next study, which would support FDA approval.
The news, which sent Momenta’s share price up about 15% yesterday, suggests the company has a shot against Argenx, a Belgian drug maker whose myasthenia gravis treatment could be up for approval later this year.
Read more.
.png)
No hay comentarios:
Publicar un comentario